Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis

被引：0
|
作者：
Killion, Lisa [1 ]
Alsharqi, Ali [1 ]
Kirby, Brian [1 ]
机构：
[1] St Vincents Hosp, Dublin, Ireland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
D O I：
10.1093/bjd/ljad113.113
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P85
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis
    Killion, Lisa
    Alsharqi, Ali
    Kirby, Brian
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (04) : 397 - 398
  • [2] Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis
    Nielsen, Valdemar Wendelboe
    Lund, Tamara Theresia
    Gniadecki, Robert
    Olsen, Rasmus Huan
    Nissen, Christoffer Valdemar
    Schwensen, Jakob Ferlov Baselius
    Thomsen, Simon Francis
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [3] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [4] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [5] Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
    Montero-Vilchez, Trinidad
    Cuenca-Barrales, Carlos
    Rodriguez-Tejero, Andrea
    Martinez-Lopez, Antonio
    Arias-Santiago, Salvador
    Molina-Leyva, Alejandro
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [6] Switching from adalimumab originator to biosimilar: clinical experience in hidradenitis suppurativa patients
    Montero-Vilchez, Trinidad
    Rodriguez-Tejero, Andrea
    Sanchez-Diaz, Manuel
    Arias-Santiago, Salvador
    Molina-Leyva, Alejandro
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 80 - 80
  • [7] REAL-WORLD EXPERIENCE ON SWITCHING ADALIMUMAB ORIGINATOR TO BIOSIMILAR IN INFLAMMATORY ARTHRITIS - A RETROSPECTIVE STUDY
    Yeoh, S. A.
    Saxby, K.
    Barron, A.
    Moore, S.
    Gani, S.
    Ehrenstein, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1458 - 1458
  • [8] Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis
    Song, Seok Hyeon
    Woo, Se Joon
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024, 32 (08) : 1755 - 1759
  • [9] Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
    Bruni, Cosimo
    Gentileschi, Stefano
    Pacini, Giovanni
    Bardelli, Marco
    Tofani, Lorenzo
    Bartoli, Francesca
    Baldi, Caterina
    Cometi, Laura
    Fiori, Ginevra
    Nacci, Francesca
    Cantarini, Luca
    Guiducci, Serena
    Moggi-Pignone, Alberto
    Frediani, Bruno
    Matucci-Cerinic, Marco
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [10] Evaluation of the nocebo effect after switching from etanercept or adalimumab originator to a biosimilar: a retrospective study of patients with inflammatory rheumatism
    Hagege, O.
    Brevet, P.
    Gerard, B.
    Duhamel, E.
    Mihailescu, S. -d.
    Alcaix, D.
    Weber, A. -J
    Marcelli, C.
    Grosjean, J.
    Varin, R.
    Lequerre, T.
    Vittecoq, O.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2025, 43 (01) : 87 - 95
12345